Home treatment with Elaprase® and Naglazyme® is safe in patients with mucopolysaccharidoses types II and VI, respectively
Author:
Publisher
Wiley
Subject
Genetics (clinical),Genetics
Link
http://www.springerlink.com/index/pdf/10.1007/s10545-008-0980-0
Reference5 articles.
1. Cox-Brinkman J, Timmermans RG, Wijburg FA, et al (2007) Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe. J Inherit Metab Dis. 30: 984. doi: 10.1007/s10545-007-0686-8 .
2. Harmatz P, Giugliani R, Schwartz I, et al (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or RHASB), and follow on, open label extension study. J Pediatr 148: 533–539. doi: 10.1016/j.jpeds.2005.12.014 .
3. Hughes DA, Milligan A, Mehta A (2007) Home therapy for lysosomal storage disorders. Br J Nurs 16: 1384, 1386–1389.
4. Milligan A, Hughes A, Goodwin S, Richfield L, Mehta A (2006) Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs 15: 330–333.
5. Muenzer J, Wraith JE, Beck M, et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8: 465–473. doi: 10.1097/01.gim.0000232477.37660.fb .
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review;International Journal of Molecular Sciences;2024-08-06
2. Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond;Orphanet Journal of Rare Diseases;2023-10-27
3. Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions;BioDrugs;2023-06-16
4. Inflammatory process and oxidative/nitrative stress: in vivo study in mucopolysaccharidosis type IV A patients under long-term enzyme replacement therapy;Archives of Biochemistry and Biophysics;2023-03
5. Difficulties Associated with Enzyme Replacement Therapy for Mucopolysaccharidoses;Turkish Archives of Pediatrics;2021-11-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3